Whole spectrum analysis of ligand efficacy at constitutively active human wild-type and S267K 5-HT6 receptors in HEK-293F cells

Journal of Pharmacological and Toxicological Methods

Volumn 55, Issue 2, 2007, Pages 144-150

  Romero, Gonzalo ^a   Pujol, Marta ^a   Pérez, Pilar ^a   Buschmann, Helmut ^a   Pauwels, Petrus J ^a  

^a Laboratorios Dr Esteve SA   (Spain)

Author keywords

Adenylyl cyclase; Constitutive activation; Cyclic AMP (cAMP); HEK 293F cell line; Human 5 HT6 receptor; Ligand efficacy; Methods; Mutagenesis

Indexed keywords

1 BENZENESULFONYL 5 METHOXY N,N DIMETHYLTRYPTAMINE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; CYCLIC AMP; E 6801; LIGAND; RECOMBINANT RECEPTOR; SEROTONIN; SEROTONIN 6 RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROPORATION; FLUORESCENCE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MONITORING; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPORATION; HUMANS; KIDNEY; LIGANDS; MUTAGENESIS, SITE-DIRECTED; MUTATION; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SIGNAL TRANSDUCTION; SULFONAMIDES; THIOPHENES; TRYPTAMINES;

EID: 33846860428     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2006.04.007     Document Type: Article

References (26)

1. Abate C., Kolanos R., Dukat M., Setola V., Roth B.L., and Glennon R.A. Interaction of chiral MS-245 analogs at h5-HT6 receptors. Bioorganic and Medicinal Chemistry Letters 15 (2005) 3510-3513
2. Boess F.G., Monsma F.J., Carolo C., Meyer V., Rudler A., Zwingelstein C., et al. Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology 36 (1997) 713-720
3. Bromidge S.M., Brown A.M., Clarke S.E., Dodgson K., Gager T., Grassam H.L., et al. 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon-amide (SB-271046): A potent, selective, and orally bioavailable 5-HT6 receptor antagonist. Journal of Medicinal Chemistry 42 (1999) 202-205
4. 6 receptor. Drugs of the Future 30 (2005) 479-495
5. Furchgott R.F. The use of b-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Advances in Drug Research 3 (1966) 21-35
6. Gabriel D., Vernier M., Pfeifer M.J., Dasen B., Tenaillon L., and Bouhelal R. High throughput screening technologies for direct cyclic AMP measurement. Assay in Drug Development Technology 1 (2003) 291-303
7. Hirst W.D., Abrahamsen B., Blaney F.E., Calver A.R., Aloj L., Price G.H., et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Molecular Pharmacology 64 (2003) 1295-1308
8. Holenz J., Merce R., Diaz J.L., Guitart X., Codony X., Dordal A., et al. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. Journal of Medicinal Chemistry 48 (2005) 1781-1795
9. Holenz J., Pauwels P.J., Diaz J.L., Mercé R., Codony X., and Buschmann H. Recent development of 5-HT6 ligands as potential cognitive enhancers and anti-obesity compounds. Drug Discovery Today 11 (2006) 283-299
10. Kenakin T. Efficacy as a vector: The relative prevalence and paucity of inverse agonism. Molecular Pharmacology 65 (2004) 2-11
11. Kohen R., Fashingbauer L.A., Heidmann D.E., Guthrie C.R., and Hamblin M.W. Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Brain Research. Molecular Brain Research 90 (2001) 110-117
12. Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E., et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. Journal of Neurochemistry 66 (1996) 47-56
13. Merce-Vidal, R., Andaluz-Mataro, B., & Frigola-Constansa, J. (2003). Preparation of N-(1H-indol-5-yl) sulfonamide derivatives with 5-HT6 receptor antagonist activity, their preparation, and their application as medicaments for CNS diseases. WO 2003/042175 A1, Laboratorios Dr. Esteve S.A.
14. Mitchell E.S., and Neumaier J.F. 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacology & Therapeutics 108 (2005) 320-333
15. Pauwels P.J., Tardif S., Wurch T., and Colpaert F.C. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: Evidence for inverse agonism. Journal of Pharmacology and Experimental Therapeutics 292 (2000) 654-663
16. Pauwels P.J., and Wurch T. Amino acid domains involved in constitutive activation of G-protein-coupled receptors. Molecular Neurobiology 17 (1998) 109-135
17. Purohit A., Herrick-Davis K., and Teitler M. Creation, expression and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor. Synapse 47 (2003) 218-224
18. Purohit A., Smith C., Herrick-Davis K., and Teitler M. Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: Inverse agonist activity of antipsychotic drugs. Psychopharmacology 179 (2005) 461-469
19. Reavill C., and Rogers D.C. The therapeutic potential of 5-HT6 receptor antagonists. Current Opinion in Investigational Drugs 2 (2001) 104-109
20. Routledge C., Bromidge S.M., Moss S.F., Price G.W., Hirst W., Newman H., et al. Characterization of SB-271046: A potent, selective and orally active 5-HT6 receptor antagonist. British Journal of Pharmacology 130 (2000) 1606-1612
21. Ruat M., Traiffort E., Arrang J.M., Tardivel-Lacombe J., Diaz J., Leurs R., et al. A novel rat serotonin (5-HT6) receptor: Molecular cloning, localization and stimulation of cAMP accumulation. Biochemical and Biophysical Research Communications 193 (1993) 268-276
22. Schoeffter P., and Waeber C. 5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes. Naunyn-Schmiedeberg's Archives of Pharmacology 350 (1994) 356-360
23. Sebben M., Ansana Y.H., Bockaert J., and Dumuis A. 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. NeuroReport 5 (1994) 2553-2557
24. Sleight A.J., Boess F.G., Bos M., Levet-Trafit B., Riemer C., and Bourson A. Characterization of Ro 04-6790 and Ro 63-0563: Potent and selective antagonists at human and rat 5-HT6 receptors. British Journal of Pharmacology 124 (1998) 556-562
25. Teitler M., Herrick-Davis K., and Purohit A. Constitutive activity of G-protein coupled receptors: Emphasis on serotonin receptors. Current Topics in Medicinal Chemistry 2 (2002) 529-538
26. Woolley M.L., Marsden C.A., and Fone K.C. 5-ht6 receptors. Current Drug Targets. CNS and Neurological Disorders 3 (2004) 59-79